Pfizer has reached a tentative agreement to settle thousands of federal Depo-Provera® brain tumor lawsuits. While the proposed settlement is not yet final, it could have important implications for women who have filed or may still be eligible to file claims.
Depo-Provera Meningioma Settlement Could Resolve Thousands of Claims
Pfizer has reached an agreement in principle to resolve thousands of federal Depo-Provera® brain tumor lawsuits ahead of the first bellwether trial. This marks a major development for women who have already filed claims and those who may still be eligible to do so.
If finalized, the settlement could resolve a substantial portion of the federal multidistrict litigation (MDL), which now includes more than 5,800 lawsuits alleging that Depo-Provera led to meningioma brain tumors.
While the terms have not been disclosed, the agreement represents a major milestone in one of the country’s fastest-moving pharmaceutical mass torts.
Her Case Matters is monitoring the settlement negotiations closely and will continue to provide updates for women and families impacted by a Depo-Provera brain tumor. Find out your eligibility to pursue Depo-Provera compensation with a free case review.
Depo Trial Deadline Vacated But Scientific Testimony Moves Forward
In June 2026, Pfizer announced that it had reached a tentative agreement with plaintiffs’ leadership for the federal Depo-Provera MDL pending in the U.S. District Court for the Northern District of Florida.
Following this, Judge M. Casey Rodgers vacated deadlines in the first bellwether case, which had been scheduled for trial in December 2026. However, the court has allowed expert scientific testimony to continue until September 18, 2026 while the parties work to finalize the deal.
Pfizer has not admitted liability or wrongdoing, and the company has not released financial terms or eligibility requirements for the proposal.
If finalized, the agreement is expected to provide an opportunity for qualifying plaintiffs with cases pending in the federal Depo-Provera MDL to resolve their claims.
The proposal does not automatically resolve lawsuits pending outside the federal MDL. Also, the court’s decision to continue the hearing on expert scientific testimony suggests the litigation could move forward for claims that fall outside this settlement agreement.
Studies Link Depo-Provera to Meningiomas
The litigation has been driven in part by emerging scientific evidence linking long-term use of Depo-Provera to an increased risk of a meningioma.
A 2025 study published in JAMA Neurology reported that women who used Depo-Provera had much greater odds of developing a meningioma than women who did not. Earlier research published in the BMJ reached similar conclusions.
In December 2025, the U.S. Food and Drug Administration approved updated labeling for Depo-Provera warning of an increased risk of meningiomas associated with prolonged use. This brought it more in line with warnings provided in several other countries.
Help Pursuing Justice & Compensation for Depo-Provera Brain Tumors
No Depo-Provera settlement amounts have been announced yet. If the proposed settlement is finalized, compensation is expected to vary based on various factors.
These factors include:
- Duration of Depo-Provera use
- Lost income
- Severity of the diagnosis
- Treatment received
- Other damages
Women who have not yet filed a lawsuit may still have an opportunity to pursue compensation. Attorneys continue to investigate claims involving women who used Depo-Provera and were later diagnosed with meningioma brain or spinal tumors.
Because statutes of limitations vary by state, women are encouraged to seek legal guidance promptly rather than wait for the settlement process to conclude.
At Her Case Matters, we’re ready to support women facing a meningioma after using Depo-Provera. Get a free case review or call (877) 640-6101 now to find out if you can file a claim with help from our legal partners.
